Drug Cost Management Report - Johnson & Johnson officials discussed new indications for Topamax - Brief Article
* Johnson & Johnson officials discussed new indications for Topamax (topiramate), during a conference call on the company’s second quarter 2003 earnings. Topamax is a widely prescribed drug with indications for seizure disorders and bipolar disorder. With its recent launch of Axert for migraine headaches, the company is entering the migraine market, but its bigger plans are for Topamax as a preventive therapy for migraines.
Most Popular
10 Jobs That Pay $30 An Hour
3 Questions No Job Seeker Ever Wants To Be Asked?
5 Regular Mistakes In Public Speaking
13 Job Interview Mistakes To Avoid
Public Speaking: 7 Secrets Of Great Public Speakers
Data presented at a recent meeting of the American Headache Society showed that 52% of patients had a 50% or greater reduction in the number of migraines when treated with 100 milligrams of Topamax, 27% had at least a 75% reduction, and 6% had complete elimination of their migraine attacks. Even more exciting for the Topamax team, the product has shown some clinical evidence that it may have metabolic action in diabetics, lowering body weight and normalizing blood sugar levels.
COPYRIGHT 2003 Atlantic Information Services, Inc.
COPYRIGHT 2003 Gale Group
